Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Company Deals

Regeneron Wins Auction for 23andMe’s Core Business Units

Fineline Cube May 21, 2025

US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid...

Company Drug

GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma

Fineline Cube May 21, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Deals

Accurate Biotechnology Secures RMB 100M in Series B Funding for Organoid Technology

Fineline Cube May 21, 2025

Accurate Biotechnology, a Guangzhou-based biotech focused on organoid technology, reportedly raised RMB 100 million (USD...

Company Drug

Hainan Shuangcheng’s Generic Eptifibatide Gains TGA Marketing Approval in Australia

Fineline Cube May 21, 2025

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia’s Therapeutic...

Company Medical Device

Stryker’s OptaBlate BVN System Gains FDA 510(k) Clearance

Fineline Cube May 21, 2025

US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system...

Company Deals

Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis

Fineline Cube May 21, 2025

Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...

Company Drug

Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC

Fineline Cube May 21, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received Fast...

Company Deals

Porton and Hualong Biological Partner to Advance MATC Therapy

Fineline Cube May 21, 2025

Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...

Company Drug

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment

Fineline Cube May 20, 2025

France-based AB Science SA (EPA: AB) reported receiving patent protection in China for its lead...

Company Drug

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials

Fineline Cube May 20, 2025

China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...

Company Deals

Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China

Fineline Cube May 20, 2025

US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...

Company Drug

Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment

Fineline Cube May 20, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...

Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

Fineline Cube May 20, 2025

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Fineline Cube May 20, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...

Company Drug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Fineline Cube May 20, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...

Company Deals

Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million

Fineline Cube May 19, 2025

Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...

Company

Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License

Fineline Cube May 19, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma

Fineline Cube May 19, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...

Company Medical Device

Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval

Fineline Cube May 19, 2025

China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...

Company Drug

Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain

Fineline Cube May 19, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...

Posts pagination

1 … 96 97 98 … 602

Recent updates

  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.